Last reviewed · How we verify
WR 279,396 with Gauze and Tape Dressing
WR 279,396 with Gauze and Tape Dressing is a Small molecule drug developed by U.S. Army Medical Research and Development Command. It is currently in Phase 2 development.
At a glance
| Generic name | WR 279,396 with Gauze and Tape Dressing |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WR 279,396 with Gauze and Tape Dressing CI brief — competitive landscape report
- WR 279,396 with Gauze and Tape Dressing updates RSS · CI watch RSS
- U.S. Army Medical Research and Development Command portfolio CI
Frequently asked questions about WR 279,396 with Gauze and Tape Dressing
What is WR 279,396 with Gauze and Tape Dressing?
WR 279,396 with Gauze and Tape Dressing is a Small molecule drug developed by U.S. Army Medical Research and Development Command.
Who makes WR 279,396 with Gauze and Tape Dressing?
WR 279,396 with Gauze and Tape Dressing is developed by U.S. Army Medical Research and Development Command (see full U.S. Army Medical Research and Development Command pipeline at /company/u-s-army-medical-research-and-development-command).
What development phase is WR 279,396 with Gauze and Tape Dressing in?
WR 279,396 with Gauze and Tape Dressing is in Phase 2.